Latest News and Press Releases

Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated business combination between the...

Issuer name: Ultimovacs ASA Ex. date: 18 December 2024 Type of corporate action: Potential repair offering  Other information: Any repair offering is subject to the prior publication of a...

Reference is made to the stock exchange announcement by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS...

Reference is made to the stock exchange announcement by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS (the "Business...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION...

Oslo, November 6, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its third quarter 2024 results...

Oslo, October 31, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its third...

Oslo, October 25, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the results from Phase II...

Oslo, September 11, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company has agreed...

Oslo, September 9, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces the presentation of updated data...